WO2014194245A3 - Inhibiteurs de cdk8 et leurs utilisations - Google Patents

Inhibiteurs de cdk8 et leurs utilisations Download PDF

Info

Publication number
WO2014194245A3
WO2014194245A3 PCT/US2014/040320 US2014040320W WO2014194245A3 WO 2014194245 A3 WO2014194245 A3 WO 2014194245A3 US 2014040320 W US2014040320 W US 2014040320W WO 2014194245 A3 WO2014194245 A3 WO 2014194245A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdk8
disorders
compounds
kinases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/040320
Other languages
English (en)
Other versions
WO2014194245A2 (fr
Inventor
Donna L. Romero
Divya Chaudhary
Shaughnessy Robinson
Craig E. Masse
Michael J. Morin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nimbus Iris Inc
Original Assignee
Nimbus Iris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Iris Inc filed Critical Nimbus Iris Inc
Publication of WO2014194245A2 publication Critical patent/WO2014194245A2/fr
Publication of WO2014194245A3 publication Critical patent/WO2014194245A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés consistant à utiliser les composés représentés par la formule (I); et des compositions associées pour l'inhibition de CDK8, et le traitement de troubles médiés par CDK8.
PCT/US2014/040320 2013-05-31 2014-05-30 Inhibiteurs de cdk8 et leurs utilisations Ceased WO2014194245A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829840P 2013-05-31 2013-05-31
US61/829,840 2013-05-31

Publications (2)

Publication Number Publication Date
WO2014194245A2 WO2014194245A2 (fr) 2014-12-04
WO2014194245A3 true WO2014194245A3 (fr) 2015-01-29

Family

ID=51989541

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/040320 Ceased WO2014194245A2 (fr) 2013-05-31 2014-05-30 Inhibiteurs de cdk8 et leurs utilisations
PCT/US2014/040243 Ceased WO2014194201A2 (fr) 2013-05-31 2014-05-30 Inhibiteurs de cdk8 et applications de ceux-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/040243 Ceased WO2014194201A2 (fr) 2013-05-31 2014-05-30 Inhibiteurs de cdk8 et applications de ceux-ci

Country Status (1)

Country Link
WO (2) WO2014194245A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2890911A1 (fr) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20210322651A1 (en) * 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
AU2016348659B2 (en) * 2015-11-03 2022-07-28 Apriligen, Inc. Compounds for treatment of hypoproliferative disorders
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
WO2019068613A1 (fr) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh Nouveaux composés de [1,6]naphthyridine et dérivés utilisés en tant qu'inhibiteurs de cdk8/cdk19
WO2020132384A1 (fr) 2018-12-21 2020-06-25 Celgene Corporation Inhibiteurs thiénopyridine de ripk2
CN113677341B (zh) 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
EP4065111A4 (fr) 2019-11-26 2023-09-20 Dana-Farber Cancer Institute, Inc. Inhibiteurs azaindoliques puissants et sélectifs de cdk8 et cdk19
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
US20250018033A1 (en) 2021-11-24 2025-01-16 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
MX2024006370A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
EP4600352A1 (fr) 2022-09-26 2025-08-13 Kyoto University Procédé de production de lymphocytes t
EP4596684A1 (fr) 2022-09-26 2025-08-06 Regcell Co., Ltd. Lymphocytes t régulateurs induits contenant un récepteur antigénique chimérique (car)
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물
JPWO2024204553A1 (fr) 2023-03-29 2024-10-03

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US20060235034A1 (en) * 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US20110282056A1 (en) * 2008-01-22 2011-11-17 Merck Patent Gmbh Protein kinase inhibitors and use thereof
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20130231328A1 (en) * 2012-01-10 2013-09-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US20060235034A1 (en) * 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US20110282056A1 (en) * 2008-01-22 2011-11-17 Merck Patent Gmbh Protein kinase inhibitors and use thereof
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20130231328A1 (en) * 2012-01-10 2013-09-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADEPU ET AL.: "Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation.", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 29, 2012, pages 5554 - 5569, XP055232212, Retrieved from the Internet <URL:http://www.researchgate.net/publication/227342543_Novel_thieno23-dpyrimidines_their_design_synthesis_crystal_structure_analysis_and_pharmacological_evaluation> [retrieved on 20141107], DOI: doi:10.1039/c2ob25420d *

Also Published As

Publication number Publication date
WO2014194245A2 (fr) 2014-12-04
WO2014194201A2 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014194245A3 (fr) Inhibiteurs de cdk8 et leurs utilisations
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
NZ720511A (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
WO2014143242A8 (fr) Composés utiles en tant qu&#39;inhibiteurs de la kinase atr
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
MX368042B (es) COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR).
MX378957B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
MX2012013081A (es) Compuestos utiles como inhibidores de cinasa atr.
UA116774C2 (uk) Інгібітори серин/треонінкінази
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
MX2011006503A (es) Derivados de pirazina utiles como inhibidores de la cinasa de atr.
MX375902B (es) Inhibidores de serina/treonina cinasa.
WO2013163190A8 (fr) Inhibiteurs d&#39;adn pk
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
HK1223096A1 (zh) 用作par-2信號通路抑制劑的咪唑並噠嗪
MX370906B (es) Inhibidores de serina/treonina cinasa.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
WO2014194242A3 (fr) Inhibiteurs de flt3 et leurs utilisations
WO2013084216A3 (fr) Composés hétéroaryle et utilisations de ceux-ci
WO2015155680A3 (fr) Dérivés de pyrazole en tant qu&#39;inhibiteurs de la dihydroorotate déshydrogénase (dhodh)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14804454

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14804454

Country of ref document: EP

Kind code of ref document: A2